A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability

Monica Corada, Lucia Zanetta, Fabrizio Orsenigo, Ferruccio Breviario, Maria Grazia Lampugnani, Sergio Bernasconi, Francesca-Fang Liao, Daniel J. Hicklin, Peter Bohlen, Elisabetta Dejana

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Vascular endothelial cadherin (VE-cadherin) is an endothelial-specific, trans-membrane protein that promotes homophilic cell adhesion. Inhibition of VE-cadherin by the blocking monoclonal antibody (mAb) BV13 inhibited angiogenesis and tumor growth in vivo. However, this effect was accompanied by a marked increase in lung and heart permeability. In the present paper, we characterize a different VE-cadherin mAb (BV14) that is able to inhibit angiogenesis without affecting vascular permeability. In vitro studies show that BV14, in contrast to BV13, did not increase paracellular permeability of endothelial monolayers and did not disrupt VE-cadherin clusters at junctions. However, both antibodies could inhibit formation of vascularlike structures in collagen gels and increase migration of endothelial cells into wounded areas. In vivo, BV14 and BV13 were equally active in inhibiting angiogenesis in the mouse cornea and in reducing the growth of hemangioma and C6 glioma. In contrast to BV13, BV14 did not change vascular permeability in all the organs tested and at any dose used. BV14 and BV13 bind to VE-cadherin extracellular repeats EC4 and EC1, respectively. We propose that, in resting vessels, where junctions are stable and well-structured, antibody binding to EC1 but not EC4 disrupts their organization and increases permeability. In contrast, in growing vessels, where endothelial cells are migrating and junctions are weaker, antibody binding to EC4 may be sufficient to disrupt cell-to-cell adhesion and inhibit assembly of new vascular structures.

Original languageEnglish (US)
Pages (from-to)905-911
Number of pages7
JournalBlood
Volume100
Issue number3
DOIs
StatePublished - Aug 1 2002

Fingerprint

Tumors
Permeability
Monoclonal Antibodies
Cell adhesion
Endothelial cells
Capillary Permeability
Neoplasms
Cell Adhesion
Antibodies
Endothelial Cells
Blocking Antibodies
Intercellular Junctions
Hemangioma
Growth
Glioma
Cornea
Blood Vessels
Monolayers
Membrane Proteins
Collagen

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Corada, M., Zanetta, L., Orsenigo, F., Breviario, F., Lampugnani, M. G., Bernasconi, S., ... Dejana, E. (2002). A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood, 100(3), 905-911. https://doi.org/10.1182/blood.V100.3.905

A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. / Corada, Monica; Zanetta, Lucia; Orsenigo, Fabrizio; Breviario, Ferruccio; Lampugnani, Maria Grazia; Bernasconi, Sergio; Liao, Francesca-Fang; Hicklin, Daniel J.; Bohlen, Peter; Dejana, Elisabetta.

In: Blood, Vol. 100, No. 3, 01.08.2002, p. 905-911.

Research output: Contribution to journalArticle

Corada, M, Zanetta, L, Orsenigo, F, Breviario, F, Lampugnani, MG, Bernasconi, S, Liao, F-F, Hicklin, DJ, Bohlen, P & Dejana, E 2002, 'A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability', Blood, vol. 100, no. 3, pp. 905-911. https://doi.org/10.1182/blood.V100.3.905
Corada, Monica ; Zanetta, Lucia ; Orsenigo, Fabrizio ; Breviario, Ferruccio ; Lampugnani, Maria Grazia ; Bernasconi, Sergio ; Liao, Francesca-Fang ; Hicklin, Daniel J. ; Bohlen, Peter ; Dejana, Elisabetta. / A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. In: Blood. 2002 ; Vol. 100, No. 3. pp. 905-911.
@article{9062eaf2cb7845cbb2ebc3e96502c344,
title = "A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability",
abstract = "Vascular endothelial cadherin (VE-cadherin) is an endothelial-specific, trans-membrane protein that promotes homophilic cell adhesion. Inhibition of VE-cadherin by the blocking monoclonal antibody (mAb) BV13 inhibited angiogenesis and tumor growth in vivo. However, this effect was accompanied by a marked increase in lung and heart permeability. In the present paper, we characterize a different VE-cadherin mAb (BV14) that is able to inhibit angiogenesis without affecting vascular permeability. In vitro studies show that BV14, in contrast to BV13, did not increase paracellular permeability of endothelial monolayers and did not disrupt VE-cadherin clusters at junctions. However, both antibodies could inhibit formation of vascularlike structures in collagen gels and increase migration of endothelial cells into wounded areas. In vivo, BV14 and BV13 were equally active in inhibiting angiogenesis in the mouse cornea and in reducing the growth of hemangioma and C6 glioma. In contrast to BV13, BV14 did not change vascular permeability in all the organs tested and at any dose used. BV14 and BV13 bind to VE-cadherin extracellular repeats EC4 and EC1, respectively. We propose that, in resting vessels, where junctions are stable and well-structured, antibody binding to EC1 but not EC4 disrupts their organization and increases permeability. In contrast, in growing vessels, where endothelial cells are migrating and junctions are weaker, antibody binding to EC4 may be sufficient to disrupt cell-to-cell adhesion and inhibit assembly of new vascular structures.",
author = "Monica Corada and Lucia Zanetta and Fabrizio Orsenigo and Ferruccio Breviario and Lampugnani, {Maria Grazia} and Sergio Bernasconi and Francesca-Fang Liao and Hicklin, {Daniel J.} and Peter Bohlen and Elisabetta Dejana",
year = "2002",
month = "8",
day = "1",
doi = "10.1182/blood.V100.3.905",
language = "English (US)",
volume = "100",
pages = "905--911",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability

AU - Corada, Monica

AU - Zanetta, Lucia

AU - Orsenigo, Fabrizio

AU - Breviario, Ferruccio

AU - Lampugnani, Maria Grazia

AU - Bernasconi, Sergio

AU - Liao, Francesca-Fang

AU - Hicklin, Daniel J.

AU - Bohlen, Peter

AU - Dejana, Elisabetta

PY - 2002/8/1

Y1 - 2002/8/1

N2 - Vascular endothelial cadherin (VE-cadherin) is an endothelial-specific, trans-membrane protein that promotes homophilic cell adhesion. Inhibition of VE-cadherin by the blocking monoclonal antibody (mAb) BV13 inhibited angiogenesis and tumor growth in vivo. However, this effect was accompanied by a marked increase in lung and heart permeability. In the present paper, we characterize a different VE-cadherin mAb (BV14) that is able to inhibit angiogenesis without affecting vascular permeability. In vitro studies show that BV14, in contrast to BV13, did not increase paracellular permeability of endothelial monolayers and did not disrupt VE-cadherin clusters at junctions. However, both antibodies could inhibit formation of vascularlike structures in collagen gels and increase migration of endothelial cells into wounded areas. In vivo, BV14 and BV13 were equally active in inhibiting angiogenesis in the mouse cornea and in reducing the growth of hemangioma and C6 glioma. In contrast to BV13, BV14 did not change vascular permeability in all the organs tested and at any dose used. BV14 and BV13 bind to VE-cadherin extracellular repeats EC4 and EC1, respectively. We propose that, in resting vessels, where junctions are stable and well-structured, antibody binding to EC1 but not EC4 disrupts their organization and increases permeability. In contrast, in growing vessels, where endothelial cells are migrating and junctions are weaker, antibody binding to EC4 may be sufficient to disrupt cell-to-cell adhesion and inhibit assembly of new vascular structures.

AB - Vascular endothelial cadherin (VE-cadherin) is an endothelial-specific, trans-membrane protein that promotes homophilic cell adhesion. Inhibition of VE-cadherin by the blocking monoclonal antibody (mAb) BV13 inhibited angiogenesis and tumor growth in vivo. However, this effect was accompanied by a marked increase in lung and heart permeability. In the present paper, we characterize a different VE-cadherin mAb (BV14) that is able to inhibit angiogenesis without affecting vascular permeability. In vitro studies show that BV14, in contrast to BV13, did not increase paracellular permeability of endothelial monolayers and did not disrupt VE-cadherin clusters at junctions. However, both antibodies could inhibit formation of vascularlike structures in collagen gels and increase migration of endothelial cells into wounded areas. In vivo, BV14 and BV13 were equally active in inhibiting angiogenesis in the mouse cornea and in reducing the growth of hemangioma and C6 glioma. In contrast to BV13, BV14 did not change vascular permeability in all the organs tested and at any dose used. BV14 and BV13 bind to VE-cadherin extracellular repeats EC4 and EC1, respectively. We propose that, in resting vessels, where junctions are stable and well-structured, antibody binding to EC1 but not EC4 disrupts their organization and increases permeability. In contrast, in growing vessels, where endothelial cells are migrating and junctions are weaker, antibody binding to EC4 may be sufficient to disrupt cell-to-cell adhesion and inhibit assembly of new vascular structures.

UR - http://www.scopus.com/inward/record.url?scp=0036682484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036682484&partnerID=8YFLogxK

U2 - 10.1182/blood.V100.3.905

DO - 10.1182/blood.V100.3.905

M3 - Article

VL - 100

SP - 905

EP - 911

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -